Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients atⅠb stage

摘要

Objective:To investigate resistance and safety ofHHPG-19K in treating non-small cell lung cancer patients.Methods:A total of30 cases were selected and randomly divided into5 groups: threeHHPG-19K groups of different dosage(60 μg/kg/day,100 μg/kg/day,200 μg/kg/day) ,positive control group(Filgrastim, namelyG-CSF5 μg/kg/day) and negative control group.Safety indexes of5 groups were observed and compared.Results:All patients had adverse event(100%) in threeHHPG-19K groups, and increasedALP,ALT andAST were main events.The degree was mild to moderate.There was no significant difference in the incidence of adverse event between dosage groups and positive control group no difference.But the incidence of negative control group was13%, which was significantly lower than dosage groups and positive control group.Conclusions:Non-small cell lung cancer patients have satisfactory tolerance toHHPG-19K, and have no resistance.Besides, dosage at100µ g/kg is the most safe.